Your browser doesn't support javascript.
loading
Serum Cotinine and Adverse Cardiovascular Outcomes: A Cross-sectional Secondary Analysis of the nuMoM2b Heart Health Study.
Theilen, Lauren H; McNeil, Rebecca B; Hunter, Shannon; Grobman, William A; Parker, Corette B; Catov, Janet M; Pemberton, Victoria L; Ehrenthal, Deborah B; Haas, David M; Hoffman, Matthew K; Chung, Judith H; Mukhtar, Farhana; Arzumanyan, Zorayr; Mercer, Brian; Parry, Samuel; Saade, George R; Simhan, Hyagriv N; Wapner, Ronald J; Silver, Robert M.
Afiliação
  • Theilen LH; Department of Obstetrics and Gynecology, School of Medicine, University of Utah, Salt Lake City, Utah.
  • McNeil RB; Division of Biostatistics and Epidemiology, RTI International, Research Triangle Park, North Carolina.
  • Hunter S; Division of Biostatistics, RTI International, Research Triangle Park, North Carolina.
  • Grobman WA; Department of Obstetrics and Gynecology, Northwestern University, Chicago, Illinois.
  • Parker CB; Division of Biostatistics, RTI International, Research Triangle Park, North Carolina.
  • Catov JM; Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburg, Pittsburg, Pennsylvania.
  • Pemberton VL; Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute (NHLB), Bethesda, Maryland.
  • Ehrenthal DB; Department of Obstetrics and Gynecology, School of Medicine, University of Wisconsin, Madison, Wisconsin.
  • Haas DM; Department of Obstetrics and Gynecology, School of Medicine, Indiana University, Indianapolis, Indiana.
  • Hoffman MK; Department of Obstetrics and Gynecology, Christiana Care, Wilmington, Delaware.
  • Chung JH; Department of Obstetrics and Gynecology, School of Medicine, University of California-Irvine, Irvine, California.
  • Mukhtar F; Department of Obstetrics and Gynecology, School of Medicine, University of California-Irvine, Irvine, California.
  • Arzumanyan Z; Department of Biomedical Research, The Lundquist Institute, Los Angeles, California.
  • Mercer B; Department of Obstetrics and Gynecology, Case Western Reserve University, Cleveland, Ohio.
  • Parry S; Department of Maternal Fetal Medicine, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Saade GR; Division Chief of Maternal Fetal Medicine and Ultrasound, Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, Texas.
  • Simhan HN; Department of Obstetrics, Gynecology, and Reproductive Science, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Wapner RJ; Department of Obstetrics and Gynecology, Columbia University Irving Medical Center, New York, New York.
  • Silver RM; Department of Obstetrics and Gynecology, School of Medicine, University of Utah, Salt Lake City, Utah.
Am J Perinatol ; 40(12): 1311-1320, 2023 09.
Article em En | MEDLINE | ID: mdl-34359079
ABSTRACT

OBJECTIVE:

We aimed to (1) compare serum cotinine with self-report for ascertaining smoking status among reproductive-aged women; (2) estimate the relative odds of adverse cardiovascular (CV) outcomes among women by smoking status; (3) assess whether the association between adverse pregnancy outcomes (APOs) and CV outcomes varies by smoking status. STUDY

DESIGN:

We conducted a cross-sectional study of the nuMoM2b Heart Health Study. Women attended a study visit 2 to 7 years after their first pregnancy. The exposure was smoking status, determined by self-report and by serum cotinine. Outcomes included incident chronic hypertension (HTN), metabolic syndrome (MetS), and dyslipidemia. Multivariable logistic regression estimated odds ratios (ORs) for each outcome by smoking status.

RESULTS:

Of 4,392 women with serum cotinine measured, 3,610 were categorized as nonsmokers, 62 as secondhand smoke exposure, and 720 as smokers. Of 3,144 women who denied tobacco smoke exposure, serum cotinine was consistent with secondhand smoke exposure in 48 (1.5%) and current smoking in 131 (4.2%) After adjustment for APOs, smoking defined by serum cotinine was associated with MetS (adjusted OR [aOR] = 1.52, 95% confidence interval [CI] 1.21, 1.91) and dyslipidemia (aOR = 1.28, 95% CI 1.01, 1.62). When stratified by nicotine exposure, nonsmokers with an APO in their index pregnancy had higher odds of stage 1 (aOR = 1.64, 95% CI 1.32, 2.03) and stage 2 HTN (aOR = 2.92, 95% CI 2.17, 3.93), MetS (aOR = 1.76, 95% CI 1.42, 2.18), and dyslipidemia (aOR = 1.55, 95% CI 1.25, 1.91) relative to women with no APO. Results were similar when smoking exposure was defined by self-report.

CONCLUSION:

Whether determined by serum cotinine or self-report, smoking is associated with subsequent CV outcomes in reproductive-aged women. APOs are also independently associated with CV outcomes in women. KEY POINTS · Cotinine was detected in 5.7% of reported nonsmokers.. · Smoking and APOs were independently associated with CV health.. · Smoking was associated with MetS and dyslipidemia..
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Complicações na Gravidez / Poluição por Fumaça de Tabaco / Doenças Cardiovasculares / Cotinina Tipo de estudo: Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Adult / Female / Humans / Pregnancy Idioma: En Revista: Am J Perinatol Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Complicações na Gravidez / Poluição por Fumaça de Tabaco / Doenças Cardiovasculares / Cotinina Tipo de estudo: Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Adult / Female / Humans / Pregnancy Idioma: En Revista: Am J Perinatol Ano de publicação: 2023 Tipo de documento: Article